基本信息 产品详情 公司简介 推荐产品
网站主页 化合物 T13889 化合物 SLLN-15
  • 化合物 SLLN-15|T13889|TargetMol

化合物 SLLN-15|T13889|TargetMol

SLLN-15
14900 25mg 起订
19420 50mg 起订
24625 100mg 起订
上海 更新日期:2025-02-14

TargetMol中国(陶术生物)

VIP1年
联系人:邵小姐
手机:15002134094 拨打
邮箱:marketing@targetmol.cn

产品详情:

中文名称:
化合物 SLLN-15
英文名称:
SLLN-15
CAS号:
2403650-93-9
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
产品类别:
抑制剂
货号:
T13889

Product Introduction

Bioactivity

NameSLLN-15
DescriptionSLLN-15 is an oral active, selective and potent enhancer of autophagy. SLLN-15 activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) [1].
In vitroSLLN-15 (0, 1, 5, 10, 25 μM) treatment for 24 h significantly decreases overall cell viability of breast cancer cells in a dose-dependent manner [1]. SLLN-15 (100 nM and 1000 nM, 7 days) is able to equally inhibit the colony formation abilities of several breast cancer cell lines [1]. Overall, SLLN-15 induces a dose-dependent anti-proliferative activity in the TNBC cell lines MDA-MB-231 and BT-20 via induction of autophagy and autophagic flux. This induction is associated with a selective inhibition of AKT-MTOR signaling. Cell Viability Assay [1] Cell Line: TNBC cell lines BT-20 and MDA-MB-231. Concentration: 0, 1, 5, 10, 25 μM. Incubation Time: 24 hours. Result: Inhibited the proliferation of two TNBC cell lines, BT-20 and MDA-MB-231. Cell Viability Assay [1] Cell Line: TNBC cell lines (MDA-MB-231, BT-20, 4T1, MDA-MB-468), MCF-7 ( ERBB2 - ), SKBR-3 ( ERBB2 + ) and HEK293T. Concentration: 100 nM and 1000 nM. Incubation Time: 7 days. Result: Equally inhibited the colony formation abilities of several breast cancer cell lines.
In vivoSLLN-15 (30mg/kg, PO, 3 times a week) not only inhibits the growth of TNBC in animal model, but also TNBC cell progression to metastases [1]. In general, oral SLLN-15 reveals a potent anticancer and anti-metastatic activity in mice bearing TNBC [1]. Animal Model: BALB/c mice or SCID mice transplanted with mouse mammary carcinoma 4T1 cells and human breast adenocarcinoma MDA-MB-231 cells (1 X 10 6 cells/ each mouse) [1] Dosage: 30mg/kg. Administration: PO, 3 times a week for 40 days. Result: Tumor allografts grew at a slower rate compared to control groups. Significant inhibition of the number of lung metastases as visualized.
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
KeywordsSLLN 15 | SLLN15 | SLLN-15
SLLN-15|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (12年)
注册资本 589.8595万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 中间体,天然产物,生物化工,化学试剂,生物技术服务

化合物 SLLN-15相关厂家报价

内容声明
拨打电话 立即询价